Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 4: 448 - 458

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.04.006

Basic research

Association of alternative splicing and tumor immune in gastric cancer based on TCGA data set

  • Qi-sheng GU ,
  • Mi-li ZHANG ,
  • Can CAO ,
  • Ji-kun LI
Expand
  • Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 201620, China

Received date: 2020-06-04

  Online published: 2021-05-14

Supported by

National Natural Science Foundation of China(81472236)

Fold

Abstract

Objective

· To investigate the association of alternative splicing and tumor immune in gastric cancer based on The Cancer Genome Atlas (TCGA) data set.

Methods

· Transcriptomic data, genomic data and corresponding clinical information of 375 tumor tissues and 32 paired adjacent normal tissues from gastric cancer patients were separately downloaded from TCGA portal. Percent-spliced-in matrix containing 452 gastric cancer tissues and paired normal tissues were downloaded from Spliceseq database. The microarray transcriptomic data GSE15459 including 192 gastric cancer patients were downloaded from Gene Expression Omnibus (GEO). ConcensusClusterPlus package was used for classifying the samples based on splicing events. Competitive Gene Set Test Accounting for Inter-gene Correlation (CAMERA) and Gene Set Variation Analysis (GSVA) were used to apply pathway and gene set analysis. CIBERSORT was used to interrogate the condition of tumor microenvironment of samples through deconvolution of profiling of mRNA expression.

Results

· Four hundred and forty-five gastric cancer tissues and paired adjacent normal tissues were included into the study after filtering, involving 4 051 genes and 8 649 splicing events. There were aberrant splicing events existing in gastric cancer tissues compared to adjacent normal tissues. The gastric cancer samples could be divided into 4 subtypes based on different high-frequency splicing events. Many clinical characteristics like T stage, M stage, age, Lauren classification, pathological stage and histological stage among the 4 subtypes were significantly different (P<0.05). The tumor hallmark characteristics and condition of microenvironment were also marked different among the 4 subtypes. The high expression of certain splicing factors were responsible for clustering of the subtypes (log2FC > 1 and FDR < 0.05), and gene set of core splicing factors was strongly correlated to antigen presentation in tumor (Pearson R = 0.44, P = 0.000).

Conclusion

· The variation of splicing events was closely related to clinical characteristics and tumor microenvironment in gastric cancer. Expression of splicing factors dominates the variation of alternative splicing events. Certain splicing factors were expected to be biomarkers for classification of gastric cancer, and targets for improving the efficacy of immunotherapy.

Key words： alternative splicing; gastric cancer; bioinformatics; tumor microenvironment; The Cancer Genome Atlas (TCGA)

Cite this article

Qi-sheng GU , Mi-li ZHANG , Can CAO , Ji-kun LI . Association of alternative splicing and tumor immune in gastric cancer based on TCGA data set[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(4) : 448 -458 . DOI: 10.3969/j.issn.1674-8115.2021.04.006

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
2 Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: pd-1/PD-L1 blockade in melanoma[J]. Clin Ther, 2015, 37(4): 764-782.
3 Bryan LJ, Gordon LI. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy[J]. Blood Rev, 2015, 29(1): 25-32.
4 Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471.
5 Stamm S, Ben-Ari S, Rafalska I, et al. Function of alternative splicing [J]. Gene, 2005, 344: 1-20.
6 Biamonti G, Catillo M, Pignataro D, et al. The alternative splicing side of cancer [J]. Semin Cell Dev Biol, 2014, 32: 30-36.
7 Kozlovski I, Siegfried Z, Amar-Schwartz A, et al. The role of RNA alternative splicing in regulating cancer metabolism[J]. Hum Genet, 2017, 136(9): 1113-1127.
8 Ryan M, Wong WC, Brown R, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer[J]. Nucleic Acids Res, 2016, 44(d1): D1018-D1022.
9 Ooi CH, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer[J]. PLoS Genet, 2009, 5(10): e1000676.
10 Josse J, Husson F. missMDA: a package for handling missing values in multivariate data analysis [J]. J Stat Softw, 2016, 70(1): 1-31.
11 Lê S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis [J]. J Stat Softw, 2008, 25(1): 1-18.
12 Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking[J]. Bioinformatics, 2010, 26(12): 1572-1573.
13 Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation[J]. Nucleic Acids Res, 2012, 40(17): e133.
14 Liberzon A, Birger C, Thorvaldsdóttir H, et al. The molecular signatures database hallmark gene set collection [J]. Cell systems, 2015, 1(6): 417-425.
15 H?nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data [J]. BMC Bioinformatics, 2013, 14(1): 7.
16 Kahles A, Lehmann KV, Toussaint NC, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients [J]. Cancer Cell, 2018, 34(2): 211-224. e216.
17 Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. NatMethods, 2015, 12(5): 453-457.
18 Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer[J]. Immunity, 2018, 48(4): 812-830.e14.
19 Leone P, Shin EC, Perosa F, et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells[J]. J Natl Cancer Inst, 2013, 105(16): 1172-1187.
20 Oltean S, Bates DO. Hallmarks of alternative splicing in cancer[J]. Oncogene, 2014, 33(46): 5311-5318.
21 Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape[J]. Nat Immunol, 2002, 3(11): 991-998.
22 Mayeda A, Krainer AR. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2[J]. Cell, 1992, 68(2): 365-375.
23 Venables JP, Lapasset L, Gadea G, et al. MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation[J]. Nat Commun, 2013, 4: 2480.
24 Mallory MJ, Allon SJ, Qiu J, et al. Induced transcription and stability of CELF2 mRNA drives widespread alternative splicing during T-cell signaling[J]. PNAS, 2015, 112(17): E2139-E2148.
25 Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs[J]. Cell, 2015, 160(6): 1125-1134.
26 Bian Y, Wang L, Lu H, et al. Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis [J]. Biochem Biophys Res Commun, 2012, 422(1): 187-193.
Options
Outlines

/

〈 〉